Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alnylam Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Single or bilateral lung transplant recipients
Confirmed RSV infection
Greater than 90 days post current lung transplant
Rejection free for a minimum of 1 month
You may not be if
Antimicrobial therapy for known viral, bacterial, or fungal respiratory co-infection at the time of diagnosis
Bronchiolitis obliterans syndrome (BOS) Grade 3 or any state BOS with FEV1 that has not been stable for at least 3 months
Use of alemtuzumab within 9 months prior to screening; anti-thymocyte globulin(ATG) or thymoglobulin within 3 months of screening: concurrent use of \>= 0.3 mg/kg/day prednisone or equivalent as maintenance therapy
active treament for acute graft rejection
Clareo Health | Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
